Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Feb;69(2):379–381. doi: 10.1038/bjc.1994.69

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.

J A Radford 1, S Clark 1, D Crowther 1, S M Shalet 1
PMCID: PMC1968681  PMID: 7507693

Abstract

Semen analysis was performed in 14 men a median of 13.5 months after completion of VAPEC-B chemotherapy for Hodgkin's disease or non-Hodgkin's lymphoma. Semen from 12 patients contained motile spermatozoa, and in nine cases the count was > 20 million ml-1. One patient was azoospermic (VAPEC-B followed by pelvic radiotherapy) and another had a count of 21 million ml-1 but sperm were non-motile. These findings suggest that, in the majority of cases, VAPEC-B chemotherapy does not cause permanent damage to the male germinal epithelium. A more detailed study of gonadal function in males and females before and after treatment with VAPEC-B for Hodgkin's disease is currently in progress.

Full text

PDF
379

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Canellos G. P., Anderson J. R., Propert K. J., Nissen N., Cooper M. R., Henderson E. S., Green M. R., Gottlieb A., Peterson B. A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478–1484. doi: 10.1056/NEJM199211193272102. [DOI] [PubMed] [Google Scholar]
  2. Chapman R. M., Sutcliffe S. B., Rees L. H., Edwards C. R., Malpas J. S. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet. 1979 Feb 10;1(8111):285–289. doi: 10.1016/s0140-6736(79)90701-3. [DOI] [PubMed] [Google Scholar]
  3. Devita V. T., Jr, Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881–895. doi: 10.7326/0003-4819-73-6-881. [DOI] [PubMed] [Google Scholar]
  4. JACKSON H., FOX B. W., CRAIG A. W. Antifertility substances and their assessment in the male rodent. J Reprod Fertil. 1961 Nov;2:447–465. doi: 10.1530/jrf.0.0020447. [DOI] [PubMed] [Google Scholar]
  5. Nicholson W. M., Beard M. E., Crowther D., Stansfeld A. G., Vartan C. P., Malpas J. S., Fairley G. H., Scott R. B. Combination chemotherapy in generalized Hodgkin's disease. Br Med J. 1970 Jul 4;3(5713):7–10. doi: 10.1136/bmj.3.5713.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Radford J. A., Crowther D. Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: results of a pilot study in 20 patients. Ann Oncol. 1991 Jul;2(7):505–509. doi: 10.1093/oxfordjournals.annonc.a058003. [DOI] [PubMed] [Google Scholar]
  7. Sieber S. M., Correa P., Dalgard D. W., Adamson R. H. Carcinogenic and other adverse effects of procarbazine in nonhuman primates. Cancer Res. 1978 Jul;38(7):2125–2134. [PubMed] [Google Scholar]
  8. Viviani S., Bonadonna G., Santoro A., Zanini M., Zucali R., Negretti E., Valagussa P. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience. Ann Oncol. 1991 Feb;2 (Suppl 2):55–62. doi: 10.1007/978-1-4899-7305-4_9. [DOI] [PubMed] [Google Scholar]
  9. Viviani S., Santoro A., Ragni G., Bonfante V., Bestetti O., Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985 May;21(5):601–605. doi: 10.1016/0277-5379(85)90088-4. [DOI] [PubMed] [Google Scholar]
  10. Whitehead E., Shalet S. M., Blackledge G., Todd I., Crowther D., Beardwell C. G. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer. 1982 Feb 1;49(3):418–422. doi: 10.1002/1097-0142(19820201)49:3<418::aid-cncr2820490304>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES